{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:21:18Z","timestamp":1782285678293,"version":"3.54.5"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/nrd2614","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T04:36:52Z","timestamp":1220243812000},"page":"771-782","source":"Crossref","is-referenced-by-count":3728,"title":["Nanoparticle therapeutics: an emerging treatment modality for cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Mark E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd2614_CR1","first-page":"F605","volume":"288","author":"D Venturoli","year":"2005","unstructured":"Venturoli, D. & Rippe, B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge and deformability. Am. J. Physiol. 288, F605\u2013F613 (2005).","journal-title":"Am. J. Physiol."},{"key":"BFnrd2614_CR2","first-page":"6387","volume":"6","author":"Y Matsumura","year":"1986","unstructured":"Matsumura, Y. & Maeda, H. A new concept of macromolecular therapies in cancer chemotherapy: mechanism of tumortropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 6, 6387\u20136392 (1986).","journal-title":"Cancer Res."},{"key":"BFnrd2614_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jnci\/djj070","volume":"98","author":"MR Dreher","year":"2006","unstructured":"Dreher, M. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98, 335\u2013344 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrd2614_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1023\/A:1011921324952","volume":"15","author":"T Nomura","year":"1998","unstructured":"Nomura, T., Koreeda, N., Yamashita, F., Takakura, Y. & Hashida, M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res. 15, 128\u2013132 (1998).","journal-title":"Pharm Res."},{"key":"BFnrd2614_CR5","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1158\/0008-5472.CAN-05-0565","volume":"65","author":"S Hu-Lieskovan","year":"2005","unstructured":"Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984\u20138992 (2005).","journal-title":"Cancer Res."},{"key":"BFnrd2614_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3171\/jns.2005.103.2.0311","volume":"103","author":"MY Chen","year":"2005","unstructured":"Chen, M. Y. et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. 103, 311\u2013319 (2005).","journal-title":"J. Neurosurg."},{"key":"BFnrd2614_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/jcp.36.5.539","volume":"36","author":"KC Gatter","year":"1983","unstructured":"Gatter, K. C. et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539\u2013545 (1983).","journal-title":"J. Clin. Pathol."},{"key":"BFnrd2614_CR8","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","volume":"66","author":"DB Kirpotin","year":"2006","unstructured":"Kirpotin, D. B. et al. Antibody targeting of long-circulating lipidic particles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732\u20136740 (2006).","journal-title":"Cancer Res."},{"key":"BFnrd2614_CR9","doi-asserted-by":"publisher","first-page":"15549","DOI":"10.1073\/pnas.0707461104","volume":"104","author":"DW Bartlett","year":"2007","unstructured":"Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104, 15549\u201315554 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd2614_CR10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1021\/bc0501146","volume":"16","author":"SR Popielarski","year":"2005","unstructured":"Popielarski, S. R., Hu-Lieskovan, S., French, S. W., Triche, T. J. & Davis, M. E. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug. Chem. 16, 1071\u20131080 (2005).","journal-title":"Bioconjug. Chem."},{"key":"BFnrd2614_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1021\/bc0603539","volume":"18","author":"DW Bartlett","year":"2007","unstructured":"Bartlett, D. W. & Davis, M. E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18, 456\u2013468 (2007).","journal-title":"Bioconjug. Chem."},{"key":"BFnrd2614_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"E Song","year":"2005","unstructured":"Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotech. 23, 709\u2013717 (2005).","journal-title":"Nature Biotech."},{"key":"BFnrd2614_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chembiol.2006.11.015","volume":"14","author":"S Hong","year":"2007","unstructured":"Hong, S. et al. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14, 107\u2013115 (2007).","journal-title":"Chem. Biol."},{"key":"BFnrd2614_CR14","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1021\/jm060515m","volume":"49","author":"X Montet","year":"2006","unstructured":"Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R. & Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49, 6087\u20136093 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnrd2614_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/cb6003788","volume":"2","author":"CB Carlson","year":"2007","unstructured":"Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C. & Kiessling, L. L. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2, 119\u2013127 (2007).","journal-title":"ACS Chem. Biol."},{"key":"BFnrd2614_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2174\/1568011043352777","volume":"4","author":"Y Pommier","year":"2004","unstructured":"Pommier, Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle check points. Curr. Med. Chem. Anticancer Agents 4, 429\u2013434 (2004).","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"BFnrd2614_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/nar\/gkj439","volume":"34","author":"DW Bartlett","year":"2006","unstructured":"Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucl. Acid Res. 34, 322\u2013333 (2006).","journal-title":"Nucl. Acid Res."},{"key":"BFnrd2614_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/bit.21285","volume":"97","author":"DW Bartlett","year":"2007","unstructured":"Bartlett, D. W. & Davis, M. E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotech. Bioeng. 97, 909\u2013921 (2007).","journal-title":"Biotech. Bioeng."},{"key":"BFnrd2614_CR19","doi-asserted-by":"publisher","first-page":"8230","DOI":"10.1158\/1078-0432.CCR-05-1895","volume":"11","author":"WC Zamboni","year":"2005","unstructured":"Zamboni, W. C. Liposomal, nanoparticle, and conjugated formulation of anticancer agents. Clin. Cancer Res. 11, 8230\u20138234 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR20","first-page":"567","volume":"2","author":"AM Rahman","year":"2007","unstructured":"Rahman, A. M., Yusuf S. W. & Ewer, M. S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2, 567\u2013583 (2007).","journal-title":"Int. J. Nanomedicine"},{"key":"BFnrd2614_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12012-007-0014-4","volume":"7","author":"G Batist","year":"2007","unstructured":"Batist, G. Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 7, 72\u201374 (2007).","journal-title":"Cardiovasc. Toxicol."},{"key":"BFnrd2614_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","volume":"13","author":"B Uziely","year":"1995","unstructured":"Uziely, B. et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol. 13, 1777\u20131785 (1995).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR23","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1158\/1078-0432.CCR-05-0803","volume":"11","author":"AV Boddy","year":"2005","unstructured":"Boddy, A. V. et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 11, 7834\u20137840 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s11095-006-9223-y","volume":"24","author":"D Sutton","year":"2007","unstructured":"Sutton, D., Nasongkla, N., Blanco, E. & Gao, J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 24, 1029\u20131046 (2007).","journal-title":"Pharm. Res."},{"key":"BFnrd2614_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0b013e3282f14a00","volume":"19","author":"ME O'Brien","year":"2008","unstructured":"O'Brien, M. E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19, 1\u20137 (2008).","journal-title":"Anticancer Drugs"},{"key":"BFnrd2614_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/17435889.1.2.229","volume":"1","author":"AE Green","year":"2006","unstructured":"Green, A. E. & Rose P. G. Pegylated liposomal doxorubicin in ovarian cancer. Int. J. Nanomedicine 1, 229\u2013239 (2006).","journal-title":"Int. J. Nanomedicine"},{"issue":"Suppl. 4","key":"BFnrd2614_CR27","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.3816\/CLM.2007.s.018","volume":"7","author":"AA Chanan-Khan","year":"2007","unstructured":"Chanan-Khan, A. A. & Lee, K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clin. Lymphoma Myeloma 7 (Suppl. 4), S163\u2013S169 (2007).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"BFnrd2614_CR28","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom, A. et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11, 4136\u20134143 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR29","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar, W. J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin Oncol. 23, 7794\u20137803 (2005).","journal-title":"J. Clin Oncol."},{"key":"BFnrd2614_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1586\/14737140.7.7.919","volume":"7","author":"IC Henderson","year":"2007","unstructured":"Henderson, I. C. & Bhatia, V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 7, 919\u2013943 (2007).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrd2614_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris, J. M. & Chess, R. B. Effect of peglyation on pharmaceuticals. Nature Rev. Drug Discov. 2, 214\u2013221 (2003).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd2614_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0168-3659(90)90127-F","volume":"11","author":"F Fuertges","year":"1990","unstructured":"Fuertges, F. & Abuchowski, A. The clinical efficacy of poly(ethylene glycol) modified proteins. J. Control. Release 11, 139\u2013148 (1990).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","volume":"55","author":"ML Graham","year":"2003","unstructured":"Graham, M. L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55. 1293\u20131302 (2003).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrd2614_CR34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0090-9556(25)08348-5","volume":"14","author":"DH Ho","year":"1986","unstructured":"Ho, D. H. et al. Clinical pharmacology of polyethylene glycol\u2013asparaginase. Drug Metab. Disposit. 14, 349\u2013352 (1986).","journal-title":"Drug Metab. Disposit."},{"key":"BFnrd2614_CR35","first-page":"213","volume":"29","author":"J Kurtzberg","year":"1988","unstructured":"Kurtzberg, J., Moore, J. O. Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"BFnrd2614_CR36","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","volume":"96","author":"TC Abshire","year":"2000","unstructured":"Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P. & Buchanan, G. R. Weekly polyethylene glycol conjugated-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96, 1709\u20131715 (2000).","journal-title":"Blood"},{"issue":"Suppl. 16","key":"BFnrd2614_CR37","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/jco.2005.23.16_suppl.3179","volume":"26","author":"PN Cheng","year":"2005","unstructured":"Cheng, P. N. et al. Pegylated recombinant human Arginase (rhArg-peg 5000Mw) has in vitro and in vitro anti-proliferative potential and apoptotic activities in human hepatocellular carcinoma (HCC). J. Clin. Oncol. 26 (Suppl. 16), 3179 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 16","key":"BFnrd2614_CR38","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1200\/jco.2005.23.16_suppl.4139","volume":"26","author":"KA Delman","year":"2005","unstructured":"Delman, K. A. et al. Phase I\/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26 (Suppl. 16), 4139 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"G Molineux","year":"2004","unstructured":"Molineux, G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 10, 1235\u20131244 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrd2614_CR40","first-page":"3710","volume":"51","author":"H Tanaka","year":"1991","unstructured":"Tanaka, H. Satake-Ishikawa, R., Ishikawa M., Matsuki, S. & Asano, K. Pharmacokinetics of recombined human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710\u20133714 (1991).","journal-title":"Cancer Res."},{"key":"BFnrd2614_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","volume":"54","author":"YS Wang","year":"2002","unstructured":"Wang, Y. S. et al. Structural and biological characterisation of pegylated recombinant interferon a2b and its therapeutic implications. Adv. Drug Del. Rev. 54, 547\u2013570 (2002).","journal-title":"Adv. Drug Del. Rev."},{"issue":"Suppl. 16","key":"BFnrd2614_CR42","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1200\/jco.2005.23.16_suppl.7562","volume":"23","author":"L Fiaherty","year":"2005","unstructured":"Fiaherty, L., Heilbrun, L., Marsack, C. & Vaishampayan U. N. Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metatastic malignant melanomal. J. Clin. Oncol. 23 (Suppl. 16), 7562 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR43","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.2002.02.051","volume":"20","author":"R Bukowski","year":"2002","unstructured":"Bukowski, R. et al. Pegylated interferon a-2b treatment for patients with solid tumors: a phase I\/II study. J. Clin. Oncol. 20, 3841\u20133849 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes, F. A. et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 13, 903\u2013909 (2002).","journal-title":"Ann. Oncol."},{"key":"BFnrd2614_CR45","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1158\/1078-0432.CCR-05-0783","volume":"11","author":"JA Posey","year":"2005","unstructured":"Posey, J. A. 3rd et al. Phase I study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphoma. Clin. Cancer Res. 11, 7866\u20137871 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2003.03.143","volume":"21","author":"EK Rowinsky","year":"2003","unstructured":"Rowinsky, E. K. et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 21, 148\u2013157 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"BFnrd2614_CR47","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00280-008-0746-2","volume":"63","author":"L. C. Scott","year":"2008","unstructured":"Scott, L. C. et al. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adnenocarcinoma. Cancer Chemother. Pharmacol. 9 April 2008 (doi:10.1007\/s00280-008-0746-2).","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl. 7","key":"BFnrd2614_CR48","first-page":"S129","volume":"38","author":"SA Shaffer","year":"2002","unstructured":"Shaffer, S. A. et al. Proteolysis of Xyotax\u2122 by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur. J. Cancer 38 (Suppl. 7), S129 (2002).","journal-title":"Eur. J. Cancer"},{"key":"BFnrd2614_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/0-306-47932-X_6","volume":"519","author":"JW Singer","year":"2003","unstructured":"Singer, J. W. et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519, 81\u201399 (2003).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnrd2614_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00001813-200503000-00003","volume":"16","author":"JW Singer","year":"2005","unstructured":"Singer, J. W. et al. Paclitaxel poliglumex (XYOTAX; CT-2103) [XYOTAX\u2122]: an intracellularly targeted taxane. Anticancer Drugs 16, 243\u2013254 (2005).","journal-title":"Anticancer Drugs"},{"key":"BFnrd2614_CR51","unstructured":"Todd, R. et al. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate. Proc. AACR-NCI-EORTC 12th Int. Conf. Mol. Targets Cancer Therapeut. Discov. Develop. Clin. Valid. Abstract 439 (2001)."},{"issue":"Suppl. 16","key":"BFnrd2614_CR52","doi-asserted-by":"publisher","first-page":"LBA7011","DOI":"10.1200\/jco.2005.23.16_suppl.lba7011","volume":"23","author":"CJ Langer","year":"2005","unstructured":"Langer, C. J. et al. Paclitaxel poliglumex (PPX)\/carboplatin vs. Paclitaxel\/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): a phase III study. J. Clin. Oncol. 23 (Suppl. 16), LBA7011 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR53","volume-title":"Chemotherapy Foundation web site","author":"M Socinski","year":"2005","unstructured":"Socinski, M. & Ramalingham, S. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological differences between men and women: is gender-specific therapy warranted? Chemotherapy Foundation web site [online], (2005)."},{"key":"BFnrd2614_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jcb.240570211","volume":"57","author":"M Kremer","year":"1995","unstructured":"Kremer, M., Judd, J., Rifkin, B., Auszmann, J. & Oursler, M. J. Estrogen modulation of osteoclast lysosomal-enzyme secretion. J. Cell. Biochem. 57, 271\u2013279 (1995).","journal-title":"J. Cell. Biochem."},{"key":"BFnrd2614_CR55","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1158\/1078-0432.CCR-06-2821","volume":"13","author":"J Homsi","year":"2007","unstructured":"Homsi, J. et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patient with advanced solid malignancies. Clin. Cancer Res. 13, 5855\u20135861 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR56","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/bjc.1994.363","volume":"70","author":"LW Seymour","year":"1994","unstructured":"Seymour, L. W. et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636\u2013641 (1994).","journal-title":"Br. J. Cancer"},{"key":"BFnrd2614_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0168-3659(92)90088-9","volume":"19","author":"R Duncan","year":"1992","unstructured":"Duncan, R. et al. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19, 331\u2013346 (1992).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR58","first-page":"83","volume":"5","author":"P Vasey","year":"1999","unstructured":"Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug\u2013polymer conjugates. Clin. Cancer Res. 5, 83\u201394 (1999).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.bjc.6690657","volume":"81","author":"AH Thomson","year":"1999","unstructured":"Thomson, A. H. et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br. J. Cancer 81, 99\u2013107 (1999).","journal-title":"Br. J. Cancer"},{"key":"BFnrd2614_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1042\/BST0350056","volume":"35","author":"R Duncan","year":"2007","unstructured":"Duncan, R. Designing polymer conjugates as lysomsomotropic nanomedicines. Biochem. Soc. Trans. 35, 56\u201360 (2007).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd2614_CR61","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/sj.bjc.6602204","volume":"91","author":"Y Matsumura","year":"2004","unstructured":"Matsumura, Y. et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer. 91, 1775\u20131781 (2004).","journal-title":"Br. J. Cancer."},{"key":"BFnrd2614_CR62","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/sj.bjc.6601856","volume":"11","author":"S Danson","year":"2004","unstructured":"Danson, S. et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer. 11, 2085\u20132091 (2004).","journal-title":"Br. J. Cancer."},{"key":"BFnrd2614_CR63","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1200\/jco.2006.24.18_suppl.4080","volume":"24","author":"A Armstrong","year":"2006","unstructured":"Armstrong, A. et al. SP1049C as first-line therapy in advanced (inoperable or metatastic) adenocarcinoma of the oesophagus: a phase II window study. J. Clin. Oncol. 24, 4080 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR64","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","volume":"10","author":"TY Kim","year":"2004","unstructured":"Kim, T. Y. et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10, 3708\u20133716 (2004).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 18","key":"BFnrd2614_CR65","doi-asserted-by":"publisher","first-page":"10520","DOI":"10.1200\/jco.2006.24.18_suppl.10520","volume":"24","author":"KS Lee","year":"2006","unstructured":"Lee K. S. et al. Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 24, (Suppl. 18), 10520 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 18","key":"BFnrd2614_CR66","doi-asserted-by":"publisher","first-page":"14078","DOI":"10.1200\/jco.2007.25.18_suppl.14078","volume":"25","author":"Y Yen","year":"2007","unstructured":"Yen, Y. et al. First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with various solid tumors. J. Clin. Oncol. 25 (Suppl. 18), 14078 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR67","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-05-1566","volume":"12","author":"T Schluep","year":"2006","unstructured":"Schluep, T. et al. Preclinical efficacy of the camptothecin\u2013polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 12, 1606\u20131614 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR68","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/07357900500359935","volume":"23","author":"J Nemunaitis","year":"2005","unstructured":"Nemunaitis, J. et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 23, 671\u2013676 (2005).","journal-title":"Cancer Invest."},{"key":"BFnrd2614_CR69","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","volume":"20","author":"LW Seymour","year":"2002","unstructured":"Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 20, 1668\u20131676 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR70","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0168-3659(98)00124-2","volume":"57","author":"PJ Julyan","year":"1999","unstructured":"Julyan, P. J. et al. Preliminary clinical study of the distribution of HPMA copolymer-doxorubicin bearing galactosamine. J. Control. Release 57, 281\u2013290 (1999).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR71","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1073\/pnas.0701458104","volume":"104","author":"JD Heidel","year":"2007","unstructured":"Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715\u20135721 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd2614_CR72","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jmb.2007.05.011","volume":"371","author":"Y Zhou","year":"2007","unstructured":"Zhou, Y. et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371, 934\u2013947 (2007).","journal-title":"J. Mol. Biol."},{"key":"BFnrd2614_CR73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"BFnrd2614_CR74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2, 48\u201358 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrd2614_CR75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","volume":"6","author":"S Modok","year":"2006","unstructured":"Modok, S., Mellor, H. R. & Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 6, 350\u2013354 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrd2614_CR76","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2174\/138945006777709593","volume":"7","author":"S Nobili","year":"2006","unstructured":"Nobili, S., Landini, I., Giglioni, B. & Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7, 861\u2013879 (2006).","journal-title":"Curr. Drug Targets"},{"key":"BFnrd2614_CR77","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/107327480301000207","volume":"10","author":"H Thomas","year":"2003","unstructured":"Thomas, H. & Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159\u2013165 (2003).","journal-title":"Cancer Control"},{"key":"BFnrd2614_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0378-4347(97)00362-9","volume":"702","author":"X Pepin","year":"1997","unstructured":"Pepin, X. et al. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B Biomed. Sci. Appl. 702, 181\u2013191 (1997).","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"BFnrd2614_CR79","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jconrel.2003.08.005","volume":"93","author":"C Vauthier","year":"2003","unstructured":"Vauthier, C., Dubernet, C., Chauvierre, C., Brigger, I. & Couvreur, P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 93, 151\u2013160 (2003).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR80","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0168-3659(99)00063-2","volume":"60","author":"MT Peracchia","year":"1999","unstructured":"Peracchia, M. T. et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60, 121\u2013128 (1999).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jconrel.2004.12.018","volume":"103","author":"ES Lee","year":"2005","unstructured":"Lee, E. S., Na, K. & Bae, Y. H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103, 405\u2013418 (2005).","journal-title":"J. Control. Release"},{"key":"BFnrd2614_CR82","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ijc.20405","volume":"112","author":"SK Sahoo","year":"2004","unstructured":"Sahoo, S. K., Ma, W. & Labhasetwar, V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112, 335\u2013340 (2004).","journal-title":"Int. J. Cancer"},{"key":"BFnrd2614_CR83","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2007.06.010","volume":"346","author":"R Suzuki","year":"2008","unstructured":"Suzuki, R. et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 346, 143\u2013150 (2008).","journal-title":"Int. J. Pharm."},{"key":"BFnrd2614_CR84","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/JCO.1997.15.2.653","volume":"15","author":"DW Northfelt","year":"1997","unstructured":"Northfelt, D. W. et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 15, 653\u2013659 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR85","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","volume":"60","author":"C Li","year":"2008","unstructured":"Li, C. & Wallace, S. Polymer\u2013drug conjugates: recent development in clinical oncology. Adv. Drug Del. Rev. 60, 886\u2013898 (2008).","journal-title":"Adv. Drug Del. Rev."},{"key":"BFnrd2614_CR86","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.addr.2007.11.010","volume":"60","author":"Y Matsumura","year":"2008","unstructured":"Matsumura, Y. Poly(amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Del. Rev. 60, 899\u2013914 (2008).","journal-title":"Adv. Drug Del. Rev."},{"key":"BFnrd2614_CR87","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner, E. R. et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin. Cancer Res. 14, 4200\u20134205 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/10611860400015936","volume":"12","author":"PR Lockman","year":"2004","unstructured":"Lockman, P. R., Koziara, J. M., Mumper, R. J. & Allen, D. D. Nanoparticle surface charges alter blood\u2013brain barrier integrity and permeability. J. Drug Target. 12, 635\u2013641 (2004).","journal-title":"J. Drug Target."},{"key":"BFnrd2614_CR89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/toxsci\/kfj027","volume":"89","author":"JS Kim","year":"2006","unstructured":"Kim, J. S. et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci. 89, 338\u2013347 (2006).","journal-title":"Toxicol. Sci."},{"key":"BFnrd2614_CR90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2005.02.006","volume":"43","author":"C Salvador-Morales","year":"2006","unstructured":"Salvador-Morales, C. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 43, 193\u2013201 (2006).","journal-title":"Mol. Immunol."},{"key":"BFnrd2614_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3322\/CA.2007.0003","volume":"58","author":"X Wang","year":"2008","unstructured":"Wang, X., Yang, L., Chen, Z. G. & Shin, D. M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 58, 97\u2013110 (2008).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrd2614_CR92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nbt1377","volume":"26","author":"X Qian","year":"2008","unstructured":"Qian, X. et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature Biotech. 26, 83\u201390 (2008).","journal-title":"Nature Biotech."},{"key":"BFnrd2614_CR93","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho, K., Wang X., Nie, S., Chen Z.G. & Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310\u20131316 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR94","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00280-005-0091-7","volume":"57","author":"T Schluep","year":"2006","unstructured":"Schluep, T. et al. Pharmacokinetics and biodistribution of the camptohecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol. 57, 654\u2013662 (2006).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrd2614_CR95","unstructured":"Pfizer. CAMPTOSAR U.S. Physician Prescribing Information. Pfizer web site [online], (2008)."},{"key":"BFnrd2614_CR96","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-199631020-00001","volume":"31","author":"VM Herben","year":"1996","unstructured":"Herben, V. M., ten Bokkel Huinink, W. W. & Beijnen, J. H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 31, 85\u2013102 (1996).","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 16","key":"BFnrd2614_CR97","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2005.23.16_suppl.2017","volume":"23","author":"EH Kraut","year":"2005","unstructured":"Kraut, E. H. et al. Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response. J. Clin. Oncol. 23 (Suppl. 16), 2017 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 18","key":"BFnrd2614_CR98","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1200\/jco.2006.24.18_suppl.2015","volume":"24","author":"A Daud","year":"2006","unstructured":"Daud, A. et al. Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients with advanced solid tumor malignancies. J. Clin. Oncol. 24 (Suppl. 18), 2015 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd2614_CR99","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490\u20131496 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd2614_CR100","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1100\/tsw.2006.162","volume":"6","author":"K Kawakami","year":"2006","unstructured":"Kawakami, K., Nakajima, O., Morishita, R. & Nagai, R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. ScientificWorldJournal 6, 781\u2013790 (2006).","journal-title":"ScientificWorldJournal"},{"key":"BFnrd2614_CR101","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc903","volume":"2","author":"TM Allen","year":"2002","unstructured":"Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Cancer 2, 750\u2013763 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrd2614_CR102","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrc1958","volume":"6","author":"R Duncan","year":"2006","unstructured":"Duncan, R. Polymer conjugates as anticancer nanomedicines. Nature Rev. Cancer 6, 688\u2013701 (2006).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrd2614_CR103","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdh092","volume":"15","author":"M Matsumura","year":"2004","unstructured":"Matsumura, M. et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15, 517\u2013525 (2004).","journal-title":"Ann. Oncol."},{"key":"BFnrd2614_CR104","unstructured":"MedBiopharm Co., Ltd. Safety study of MBP-426 (liposomal oxaliplatin suspension for injection) to treat advanced or metastatic solid tumors. ClinicalTrials.gov web site [online], (2008)."},{"key":"BFnrd2614_CR105","unstructured":"Phan, A. et al. Open label phase I study of MBP-426, a novel formulation of oxalipatin, in patients with advanced or metastatic solid tumors. Proc. AACR-NCI-EORTC Int. Conf. Mol. Targets Cancer Therapeut. Discov. Develop. Clin. Valid. Abstract C115 (2007)."},{"key":"BFnrd2614_CR106","unstructured":"SynerGene Therapeutics, Inc. Safety Study of Infusion of SGT-53 to Treat Solid Tumors. ClinicalTrials.gov web site [online], (2008)."},{"key":"BFnrd2614_CR107","unstructured":"Calando Pharmaceuticals. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. ClinicalTrials.gov web site [online], (2008)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrd2614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd2614","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd2614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T19:32:23Z","timestamp":1738351943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd2614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["BFnrd2614"],"URL":"https:\/\/doi.org\/10.1038\/nrd2614","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}